- Plaintiff
- Passes, Bernard
- Represented By:
- Leviton, Jason (Block & Leviton LLP)
- Defense
- Amgen
- Represented By:
- Sacks, Robert (Sullivan & Cromwell, LLP)
- Defense
- Micromet
- Represented By:
- Fukumura, Koji (Cooley Godward Kronish LLP)
In this pharmaceutical Mergers and acquisition hearing, Plaintiff shareholder Bernard Passes alleged Micromet Inc. of failing in its duty to get the best price for its shareholder by agreeing to Amgen Incs offer of acquiring the company at $11 a share. The plaintiffs counsels argued to block the proposed deal between Micromet Inc. and Amgen Inc. in which Amgen was acquiring Micromet in order to gain control over the experimental Lukemia drug. The plaintiffs counsels claimed that given Micromets growth prospect and potential future earnings, the price of $11 per share was too low.
The plaintiff was represented by attorney Jason Leviton. The defense in this case comprised of Amgen Inc and Micromet Inc. Amgen Inc. was represented by attorney Robert Sacks. Micromet Inc. was represented by attorney Koji Fukumura.
Recording Disclaimer: This proceeding was recorded in full.
Copyright 2024 Courtroom Connect.